FEATURED EDITORIAL
Potency is measured in an assay; exposure is achieved in an organism. Confusing the two is a category error that still shapes hit selection.
- What The China Biotech Debate Reveals About U.S. Drug Discovery
- Closing The Loop Between AI And Experimental Biology
- Beyond Apoptosis: Context Is The Target
- Alpha-Synuclein Is Not One Target
- Early Decisions That Shape Success In CNS Drug Development And Commercialization, Part 2
- July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
FEATURED APPLICATION CONTENT
-
Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
- What The China Biotech Debate Reveals About U.S. Drug Discovery
- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
- Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- SandboxAQ Launches AQPotency, Bringing Ultrafast Virtual Screening To Drug Discovery Without A Solved Protein Structure
- DeepCyte Launches World's First Single-Cell Mechanistic Toxicity Atlas As Enterprise Pharma Pilots Advance
- Verlytix Launches As A Related Company To LyoGenesis Manufacturing
- Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted For Oral Presentation At ISMRM Workshop On X-Nuclei MR In Barcelona, Spain
- Harbour BioMed Announces NMPA Approval Of IND Application For HBM7004 For The Treatment Of Advanced Solid Tumors
- GenBio AI Builds First World Model Of The Human Cell
- Amygdala Neurosciences Announces FDA Clearance Of Investigational New Drug (IND) Application For ANS-858
- Tagomics Introduces LiquiPath, A First-In-Class cfDNA-Based Blood Test For Multi-Organ Drug Safety Monitoring
- OncoC4 Announces First Patient Dosing In Phase 1 Clinical Trial Of ONC-783 For The Treatment Of Advanced Solid Tumors
- TCS launches Agentic AI Platform To Transform Drug Development
ARCHIVED NEWSLETTER
- 08.20.26 -- Scaling Human-Relevant Science For Biologics Development
- 08.20.26 -- Target Discovery Solutions For Faster, Smarter R&D
- 08.19.26 -- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
- 08.13.26 -- When Innovation Meets Scale
- 08.13.26 -- Cellular Models Solutions That Bring Research Closer To Humans
